Searched for
HIV DRUG LENACAPAVIR
Generic HIV drug rollout to take a hit on trial pushIndia's decision to reject a waiver for local clinical trials of a new HIV drug, lenacapavir, is causing concern. Public health experts war...- Stocks in news: Glenmark Pharma, Adani Energy, Dr Reddy's, Tata Motors, Newgen SoftwareMarkets declined due to global and domestic pressures, with the Nifty testing support at 25040. Glenmark Pharma partnered with Hengrui Phar...
- HIV-prevention drug to cost $40 a year from 2027The two organizations have signed separate agreements with Indian pharmaceutical companies to produce cheaper generics of lenacapavir - a t...
- Indian drugmakers Dr Reddy's, Hetero to sell generic HIV prevention drug for $40 a yearIndian drugmakers, Dr Reddy's and Hetero Labs, will offer generic HIV prevention drugs. The price will be around $40 yearly from 2027. This...
- WHO recommends Gilead's twice-yearly injection for HIV preventionThe WHO's recommendations come at a critical moment as HIV prevention efforts stagnate with 1.3 million new HIV infections occurring in 202...
- US aid cuts halt HIV vaccine research in South Africa, with global impactSouth Africa faces setbacks in HIV research. The United States withdrew funding, impacting trials. Researchers are devastated as crucial pr...
- Lenacapavir HIV shot approved in US may enter Canada by 2026; just two injections needed a yearA twice-yearly injectable drug, lenacapavir, hailed as a breakthrough in HIV prevention, could be available in Canada by mid-2026. Develope...
- A new HIV drug promises 99.9% protection. But it's making Indian health activists wary; Why?The FDA's approval of lenacapavir, a highly effective HIV prevention drug, sparks debate in India due to its high cost of ₹24 lakh, hinderi...
- US approves Gilead's twice-yearly injection to prevent HIVThe US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hail...
- 2024 science review: The 10 most intriguing breakthroughs of the yearDespite global turmoil, 2024 saw groundbreaking scientific advancements, including discovering the moon's far side, a new HIV prevention dr...
- Twice-yearly shot could help end AIDS. But will it get to everyone who needs it?Gilead's twice-yearly HIV prevention shot was 100% effective in women and almost as good in men. The company will offer cheap generic versi...
- Quick access to key HIV drug hinges on waiver of local clinical trials: ExpertsFaster access to HIV drug lenacapavir in India hinges on the waiver of local clinical trials. Six companies, including three from India, ha...
- Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug LenacapavirEmcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention a...
- Dr Reddy's enters voluntary licensing deal with Gilead for long-acting HIV drugDr. Reddy’s has partnered with Gilead Sciences to manufacture and market the HIV drug Lenacapavir in India and 120 other countries. The agr...
- Activists sound alarm bells as Gilead seeks rights over HIV drugLenacapavir, a very expensive drug, is not available in India and many other countries. If the Indian Patent Office clears Gilead's patent ...
- Experts say a twice-yearly injection that offers 100% protection against HIV is 'stunning'The shots made by U.S. drugmaker Gilead and sold as Sunlenca are approved in the U.S., Canada, Europe and elsewhere, but only as a treatmen...
- New 'vaccine-like' HIV drug could cost just $40: ResearchersA new "vaccine-like" HIV drug that currently costs over $40,000 per person a year could be made for as little as $40, researchers estimated...
- HIV breakthrough: Drug trial shows injection twice a year is 100% effective against infectionThe trial tested whether the six-month injection of lenacapavir would provide better protection against HIV infection than two other drugs,...
Load More
